Bendroflumethiazide 2mg/5ml oral solution
Requires a prescription from a doctor or prescriber
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bendroflumethiazide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bendroflumethiazide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Neo-Naclex brand family (generic: Bendroflumethiazide)
MHRA licensed products
View all licensed products for Bendroflumethiazide on the MHRA register
WHO defined daily dose (DDD)
2.5 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Bendroflumethiazide
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Hypertension in adults: diagnosis and management (NG136)
Renal and ureteric stones: assessment and management (NG118)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
28 found
Half-life
8.5 hours
Mechanism
As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the…
Food interactions
1 warning
Human targets
6 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
8.5 hours
Protein binding
96%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1710 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:18270262 PMID:21613606 PMID:22009145 PMID:36351028 PMID:36792826
Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity)
PMID:14523450 PMID:29330545 PMID:31152168
It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential.
Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map.
Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX). Possibly induces sleep when activated by melatonin and through melatonin receptor MTNR1A-dependent dissociation of G-beta and G-gamma subunits, leading to increased sensitivity to Ca(2+) and reduced synaptic transmission PMID:32958651
PMID:21321328
Electrically silent transporter system (By similarity)
PMID:10550681 PMID:16506782 PMID:16686544 PMID:16807956 PMID:17127057 PMID:17314045 PMID:17407288 PMID:18618712 PMID:19186056 PMID:19206230
Can hydrate cyanamide to urea PMID:10550681
PMID:11327835 PMID:11802772 PMID:11831900 PMID:12056894 PMID:12171926 PMID:1336460 PMID:14736236 PMID:15300855 PMID:15453828 PMID:15667203 PMID:15865431 PMID:16106378 PMID:16214338 PMID:16290146 PMID:16686544 PMID:16759856 PMID:16807956 PMID:17127057 PMID:17251017 PMID:17314045 PMID:17330962 PMID:17346964 PMID:17540563 PMID:17588751 PMID:17705204 PMID:18024029 PMID:18162396 PMID:18266323 PMID:18374572 PMID:18481843 PMID:18618712 PMID:18640037 PMID:18942852 PMID:1909891 PMID:1910042 PMID:19170619 PMID:19186056 PMID:19206230 PMID:19520834 PMID:19778001 PMID:7761440 PMID:7901850 PMID:8218160 PMID:8262987 PMID:8399159 PMID:8451242 PMID:8485129 PMID:8639494 PMID:9265618 PMID:9398308
Can also hydrate cyanamide to urea .
PMID:10550681 PMID:11015219
Stimulates the chloride-bicarbonate exchange activity of SLC26A6 .
PMID:15990874
Essential for bone resorption and osteoclast differentiation .
PMID:15300855
Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC C03AB01
ATC C03EA13
ATC G01AE10
ATC C03AA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bendroflumethiazide
Additional database identifiers
Drugs Product Database (DPD)
9550
ChemSpider
2225
BindingDB
50238678
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10912
GenAtlas
SLC12A3
GeneCards
SLC12A3
GenBank Gene Database
U44128
GenBank Protein Database
1172161
UniProt Accession
S12A3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6284
GenAtlas
KCNMA1
GeneCards
KCNMA1
GenBank Gene Database
U13913
GenBank Protein Database
537439
Guide to Pharmacology
380
UniProt Accession
KCMA1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10910
GenAtlas
SLC12A1
GeneCards
SLC12A1
GenBank Gene Database
U58130
GenBank Protein Database
1373425
Guide to Pharmacology
968
UniProt Accession
S12A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1368
GenAtlas
CA1
GeneCards
CA1
GenBank Gene Database
X05014
GenBank Protein Database
29600
Guide to Pharmacology
2597
UniProt Accession
CAH1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1373
GenAtlas
CA2
GeneCards
CA2
GenBank Gene Database
M77181
GenBank Protein Database
179780
Guide to Pharmacology
3092
UniProt Accession
CAH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1375
GenAtlas
CA4
GeneCards
CA4
GenBank Gene Database
M83670
GenBank Protein Database
179791
Guide to Pharmacology
2599
UniProt Accession
CAH4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12014
GenAtlas
TPMT
GeneCards
TPMT
GenBank Gene Database
S62904
GenBank Protein Database
386420
UniProt Accession
TPMT_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: